LLY vs ABBV
Eli Lilly and Company vs AbbVie Inc. · Updated Mar 28, 2026
LLY — 10 winsABBV — 11 wins
Price Performance
LLY +6.78%ABBV +2.00%
Performance
| LLY | ABBV | |
|---|---|---|
| 1 Month | -14.15% | -6.60% |
| 3 Months | -18.53% | -8.71% |
| 6 Months | +22.78% | -3.97% |
| YTD | -18.36% | -8.15% |
| 1 Year | +6.12% | +4.25% |
| 3 Year | +152.20% | +36.57% |
| 5 Year | +449.95% | +98.17% |
Yearly Returns
| YTD | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LLY | -18.7% | +37.4% | +30.4% | +59.7% | +35.1% | +66.9% | +27.7% | +14.4% | +36.7% | +13.2% | -11.3% | +20.3% |
| ABBV | -8.7% | +27.3% | +11.2% | -4.6% | +19.3% | +28.4% | +19.6% | -0.8% | -6.3% | +55.0% | +8.7% | -10.1% |
Valuation
| LLY | ABBV | |
|---|---|---|
| P/E Ratio | 38.23 | 88.92 |
| Forward P/E | 26.69 | 14.13 |
| PEG Ratio | 1.85 | 7.81 |
| P/S Ratio | 13.14 | 5.93 |
| P/B Ratio | 32.28 | — |
| EV/EBITDA | 31.93 | 14.91 |
Financials
| LLY | ABBV | |
|---|---|---|
| EPS (TTM) | $22.95 | $2.36 |
| Gross Margin | +82.52% | +72.61% |
| Operating Margin | +42.85% | +27.34% |
| Net Margin | +34.41% | +10.93% |
| ROE | +77.78% | -131.16% |
| ROA | +18.35% | +3.16% |
| Debt/Equity | 1.60 | -19.98 |
Growth
| LLY | ABBV | |
|---|---|---|
| Revenue Growth YoY | +42.56% | +10.04% |
| Revenue Growth QoQ | +9.61% | +5.34% |
| EPS Growth YoY | +51.43% | +5735.36% |
| EPS Growth QoQ | +19.00% | +920.00% |
Technical
| LLY | ABBV | |
|---|---|---|
| RSI (14) | 26.41 | 35.84 |
| % From 20-Day SMA | -8.31% | -4.43% |
| % From 50-Day SMA | -12.88% | -5.35% |
| % From 200-Day SMA | -2.04% | -2.72% |
| % From 52-Week High | -22.63% | -14.28% |
| % From 52-Week Low | +40.66% | +27.66% |
Analyst Ratings
LLY
Buy(25 analysts)
Strong SellHoldStrong Buy
Price Target
$1243.95
+37.96% upside
ABBV
Buy(20 analysts)
Strong SellHoldStrong Buy
Price Target
$256.15
+25.90% upside
Overview
| LLY | ABBV | |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - General | Drug Manufacturers - General |
| Exchange | NYSE | NYSE |
| Market Cap | $856.56B | $362.60B |
| Shares Outstanding | 943.4M | 1.77B |
| Avg Volume (10D) | 3.02M | 7.99M |
| Dividend Yield | 0.69% | 3.24% |
Frequently Asked Questions
Is LLY or ABBV a better buy right now?
Based on 21 comparable metrics, ABBV leads in 11 categories while LLY leads in 10. ABBV has a consensus analyst rating with 20 analysts covering the stock. Neither stock should be purchased based on a single comparison — consider your investment goals and risk tolerance.
Which stock has better performance, LLY or ABBV?
Over the past year, LLY returned +6.12% compared to ABBV's +4.25%. In the short term (1 month), LLY returned -14.15% vs ABBV's -6.60%.
Is LLY or ABBV more expensive?
LLY trades at a P/E of 38.23 compared to ABBV's 88.92. On a price-to-sales basis, LLY trades at 13.14x vs ABBV's 5.93x. Forward P/E: LLY at 26.69 vs ABBV at 14.13.
Which stock has higher growth, LLY or ABBV?
LLY's revenue grew +42.56% year-over-year compared to ABBV's +10.04%. EPS growth: LLY at +51.43% vs ABBV at +5735.36%.
Do LLY and ABBV pay dividends?
LLY pays a dividend with a yield of 0.69%. ABBV pays a dividend with a yield of 3.24%.
Which stock do analysts prefer, LLY or ABBV?
LLY has 25 analysts with a target price of $1243.95 (+37.96% upside). ABBV has 20 analysts with a target of $256.15 (+25.90% upside).
Data updated daily. All comparisons based on latest available market data. Not investment advice.